Sagimet Biosciences to Host Virtual KOL Event, 'Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)' on May 29, 2025
Thursday, May 22, 2025 1 min read
Key Takeaway: Sagimet Biosciences to Host Virtual KOL Event, 'Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)' on May 29, 2025
Full Press Release Details
Sagimet Biosciences to Host Virtual KOL Event, 'Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)' on May 29, 2025.